Contemporary non-statin therapies for dyslipidemia management: achieving current lipid targets. (PubMed, Front Med (Lausanne)) - Sep 9, 2026 - "Third evidence indicates that non-statin therapies-including ezetimibe, bempedoic acid, PCSK9 inhibitors (evolocumab and alirocumab), and inclisiran-provide substantial LDL-C reductions and reduce cardiovascular events...Additionally, the fixed-dose combination of bempedoic acid and ezetimibe produces an approximately 36.2% reduction in LDL-C in high-risk patients...Furthermore, inflammation (measured by hsCRP) provides complementary prognostic information beyond LDL-C. This expert position paper proposes practical algorithms for a precision medicine approach in Latin America, matching treatment intensity to individual risk profiles for the primary and secondary prevention of atherosclerotic cardiovascular disease."
Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Inflammation • Metabolic Disorders • CRP
|
|
Adriana Puente-Barragán; Alberto Lorenzatti; Camila Y Ullauri-Valcárcel; Carlos I Ponte-Negretti; Esteban Ortiz-Prado; Fernando Wyss-Quintana; Isaac A Suárez Sangucho; Jorge Vasconez-Gonzalez; José G Prieto-Marin; Luz C Zárate-Correa; Máxima Mendez-Castillo; Osiris Valdez-Tiburcio; Rodrigo Alonso; Vladimir E Ullauri-Solórzano
|